News from Heart Failure 2025: SOGALDI-PEF trial results

João Pedro Ferreira

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Head-to-head comparison of disease-modifying therapies in ATTR-CM
Head-to-head comparison of disease-modifying therapies in ATTR-CM
ESC Heart Failure 2025
Head-to-head comparison of disease-modifying therapies in ATTR-CM
- Vincenzo Castiglione, MD
Greater benefit of empagliflozin in HFpEF patients with features of diastolic dysfunction
Greater benefit of empagliflozin in HFpEF patients with features of diastolic dysfunction
ESC Heart Failure 2025
Greater benefit of empagliflozin in HFpEF patients with features of diastolic dysfunction
- João Pedro Ferreira, MD, PhD
Effects of a switch in fluid management in patients with chronic HF
Effects of a switch in fluid management in patients with chronic HF
ESC Heart Failure 2025
Effects of a switch in fluid management in patients with chronic HF
- Job Herrmann, MD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
ESC Heart Failure 2025
Finerenone does not alter vascular stiffness in patients with T2D and CKD
- Atsushi Tanaka, MD, PhD